Department of Education   Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Washington DC United States (1979)

Organization Overview

First Clinical Trial
1999
NCT00062972
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

U.S. Department of Education

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aphasia (Phase 3)

Aphasia, Broca (Phase 3)

Brain Injuries (Phase 4)

Brain Injuries, Traumatic (Phase 4)

Confusion (Phase 4)

Delirium (Phase 4)

Depression (Phase 4)

Depressive Disorder (Phase 2)

Fatigue (Phase 2)

Multiple Sclerosis (Phase 3)

Neuralgia (Phase 2)

Sclerosis (Phase 3)

Spinal Cord Injuries (Phase 2)

Urinary Bladder, Neurogenic (Phase 2)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 16